Shares of Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) have been assigned a consensus broker rating score of 1.30 (Strong Buy) from the five brokers that provide coverage for the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a buy recommendation and three have issued a strong buy recommendation on the company.

Brokers have set a one year consensus price target of $33.40 for the company and are expecting that the company will post ($0.57) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Biohaven Pharmaceutical Holding Co an industry rank of 108 out of 265 based on the ratings given to related companies.

Several equities research analysts recently weighed in on the company. Needham & Company LLC assumed coverage on Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They set a “buy” rating and a $30.00 price target for the company. Morgan Stanley assumed coverage on Biohaven Pharmaceutical Holding Co in a report on Wednesday, May 31st. They set an “overweight” rating for the company. Piper Jaffray Companies assumed coverage on Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They set an “overweight” rating and a $21.00 price target for the company. Barclays PLC assumed coverage on Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They set an “overweight” rating and a $30.00 price target for the company. Finally, William Blair assumed coverage on Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They set an “outperform” rating and a $46.00 price target for the company.

Biohaven Pharmaceutical Holding Co (NASDAQ BHVN) opened at 24.40 on Friday. The company has a 50 day moving average of $25.00 and a 200 day moving average of $23.84. The firm’s market capitalization is $872.25 million. Biohaven Pharmaceutical Holding Co has a 1-year low of $17.00 and a 1-year high of $29.50.

WARNING: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/12/biohaven-pharmaceutical-holding-co-ltd-bhvn-receives-average-rating-of-strong-buy-from-analysts.html.

Biohaven Pharmaceutical Holding Co Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Get a free copy of the Zacks research report on Biohaven Pharmaceutical Holding Co (BHVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.